Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AX Other antipsychotics
N05AX14 Iloperidone
D02666 Iloperidone (USAN/INN) <US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Iloperidone
D02666 Iloperidone (USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
D02666 Iloperidone
DG03005 Serotonin-dopamine antagonist (SDA)
D02666 Iloperidone
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
D02666 Iloperidone
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
D02666 Iloperidone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D02666 Iloperidone
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D02666 Iloperidone (USAN/INN) <US>
Serotonin
HTR2
D02666 Iloperidone (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02666
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02666
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02666
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D02666